- Conditions
- Ocular Hypertension, Open Angle-glaucoma
- Interventions
- ONO-9054, Latanoprost
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Mission Hills, California • Newport Beach, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 198
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Choroidal Neovascularization
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- Cisplatin + Gemcitabine with SUBATM-itraconazole, Cisplatin + Gemcitabine
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Hydration Status
- Interventions
- Hydrate Heroes (6 packets), Hydrate Heroes (3 packets)
- Dietary Supplement
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100, Buphenyl (NaPBA)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Long Beach, California • Los Angeles, California • Stanford, California + 18 more
- Conditions
- Cervical Dystonia
- Interventions
- Corabotase, Placebo
- Biological · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Fountain Valley, California • Loma Linda, California + 7 more
- Conditions
- PTSD, Post Traumatic Stress Disorder
- Interventions
- Traditional Exposure Therapy (ET) Treatment, Stepwise Augmented Reality (AR) Component with Traditional Exposure Treatment for Nonresponders
- Behavioral
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Multiple Myeloma, Fatigue
- Interventions
- AYO light glasses (Experimental), AYO light glasses (Comparator)
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • New York, New York
- Conditions
- Pregnancy Prevention
- Interventions
- Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram
- Drug · Other
- Lead sponsor
- InnovaGyn, Inc.
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Diabetic Macular Edema
- Interventions
- Faricimab, Ranibizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more
- Conditions
- Healthy
- Interventions
- Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules)
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- HIV I Infection
- Interventions
- Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
- Drug
- Lead sponsor
- Charlotte-Paige Rolle, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Hearing Loss
- Interventions
- Phonak Audeo Infinio Sphere, Hearing aid B, Hearing aid C
- Device
- Lead sponsor
- Sonova AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Illinois
- Conditions
- Psoriatic Arthritis
- Interventions
- Zasocitinib, Active Comparator, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 50
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 44 more
- Conditions
- Behcet Syndrome
- Interventions
- Apremilast (CC-10004), Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
- Biological · Other · Drug
- Lead sponsor
- Beat AML, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Obesity, Overweight, Healthy
- Interventions
- PF-04620110, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- Gabapentin 400 mg capsules, NEURONTIN® 400 mg capsules
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Psoriasis
- Interventions
- Luma Light System, Luma Light, Occlusive Dressing
- Device
- Lead sponsor
- Illumicure Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Santa Rosa, California
- Conditions
- Healthy
- Interventions
- Nifedipine Extended Release tablets 60 mg, single dose, ADALAT® CC Extended Release Tablets 60 mg
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Interventions
- PPD10558, Atorvastatin, Placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 67
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Brief Family-Involved Treatment (B-FIT), Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Dementia, Alzheimer Disease, Relationship, Marital, Caregiver Stress Syndrome
- Interventions
- READyR A, READyR B
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 62 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Knee Osteoarthritis
- Interventions
- Mindset intervention, Active comparator
- Behavioral · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Stanford, California